Ropinirole: A Review of its Use in the Management of Parkinson's Disease

Matheson, A.J.; Spencer, C.M.
July 2000
Drugs;Jul2000, Vol. 60 Issue 1, p115
Academic Journal
Ropinirole, a non-ergoline dopamine agonist, has selective affinity for dopamine D-like receptors and little or no affinity for non-dopaminergic brain receptors. Ropinirole is indicated as adjunct therapy to levodopa in patients with advanced Parkinson's disease. It is also indicated, and recent clinical trials have focused on its use, as monotherapy in patients with early Parkinson's disease. In the symptomatic treatment of early Parkinson's disease ropinirole monotherapy was significantly more effective than placebo in 2 multicentre, randomised, double-blind trials of 3 to 12 months duration as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and Clinical Global Impression/Clinical Global Evaluation Scales. In a similarly designed 3-year comparative study with bromocriptine, ropinirole recipients showed a significant improvement in UPDRS- activities of daily living (ADL) scores; however, motor scores were similar between the 2 groups. Ropinirole and levodopa treatments were similar in efficacy as measured by UPDRS ADL scores, although ropinirole recipients showed significantly less improvement on UPDRS motor scores at the 5-year study end-point in a multicentre, randomised double-blind trial. As an adjunct therapy to levodopa in patients with more advanced Parkinson's disease, ropinirole was reported to be as effective as bromocriptine and significantly more effective than placebo. In general in the comparisons with placebo ropinirole allowed a ≥20% reduction in the concomitant dose of levodopa without compromising efficacy in a significant proportion of patients and, in some trials decreased the amount of awake time spent in the ‘off’ state (‘off’ state is defined as a gradual return to parkinsonism despite adequate medication). Ropinirole was well tolerated either as monotherapy or as an adjunct to levodopa treatment. Nausea, dizziness and somnolence were the most commonly reported adverse events and were reported at a higher incidence by patients receiving ropinirole than by those receiving placebo. In patients with early Parkinson's disease, ropinirole generally showed a similar overall tolerability profile to bromocriptine although, over a 3-year period nausea was more commonly reported with ropinirole recipients. In a 5-year study, the incidence of dyskinesia was significantly lower with ropinirole than with levodopa regardless of levodopa supplementation. Prior to the addition of supplementary levodopa 5% of ropinirole recipients had experienced dyskinesia compared with 36% of those receiving levodopa. Conclusions: In patients with early Parkinson's disease, ropinirole monotherapy was more efficacious than bromocriptine with regard to improvement in activities of daily living, and need for supplemental levodopa. Ropinirole recipients had a higher requirement for levodopa supplementation than levodopa recipients in a 5-year study, but the incidence of dyskinesia was significantly lower with ropinirole than with levodopa (markedly so in the one third of ropinirole recipients who were able to remain on monotherapy with no levodopa supplementation). Thus available data suggest that ropinirole may provide a means of treating early Parkinson's disease while minimising the risk of dyskinesia and delaying the need for supplemental levodopa in some patients. In addition, ropinirole is also efficacious in the management of more advanced Parkinson's disease in patients who are experiencing motor complications after long term levodopa use.


Related Articles

  • Comparison of the Risk of Adverse Events with Pramipexole and Ropinirole in Patients with Parkinson’s Disease: A Meta-Analysis. Etminan, Mahyar; Gill, Sudeep; Samii, Ali // Drug Safety;Apr2003, Vol. 26 Issue 6, p439 

    Background: Pramipexole and ropinirole are relatively new dopamine agonists, both of which have proven efficacy in the treatment of Parkinson’s disease. There is, however, uncertainty regarding differences in the adverse event profiles associated with each drug. Objective: To compare the...

  • Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. Iskedjian, M.; Einarson, T.R.; Iskedjian, Michael; Einarson, Thomas R // PharmacoEconomics;2003, Vol. 21 Issue 2, p115 

    Background: Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa.Objective: To examine the economic impact of reducing dyskinesias using...

  • Ropinirole.  // Reactions Weekly;11/6/2010, Issue 1326, p30 

    The article describes the case of a man who developed an inflammatory aneurysm of the abdominal aorta after receiving treatment with ropinirole for Parkinson's disease.

  • Modern management of Parkinson's disease. Davenport, Richard // Pulse;1/13/2003, Vol. 63 Issue 2, p42 

    Provides in sights on the modern management of Parkinson's disease. Use of glial derived neurotrophic factor; Etiology of Parkinson's disease; Overview of the various treatment approaches.

  • Parkinson's disease: Progress along the continuum of care. Pennachio, Dorothy L. // Patient Care;12/15/2000, Vol. 34 Issue 23, p50 

    Discusses the treatment of Parkinson's (PD) disease in the United States. Diagnosis; Identification of persons at risk for PD; Differentiating PD from patients with movement disorder called essential tremor and a variety of other conditions; Pharmacologic and treatment options. INSETS: PD: More...

  • EFFICACY AND SAFETY OF ROPINIROLE AS EARLY THERAPY FOR PARKINSON'S DISEA. Kreider, M. S.; Wilson-Lynch, K.; Gardiner, D.; Wheadon, D. E. // Gerontologist;Oct1996 Supplement, Vol. 36 Issue 1, p271 

    The efficacy and safety of ropinirole, a nonergoline, selective D2 agonist, was evaluated in a six-month, multicenter, double-blind, placebo-controlled study in early Parkinson's disease. 241 patients with limited or no exposure to dopaminergic agents were enrolled. Approximately 50% of the...

  • Treatment of early Parkinson's disease. Marsh, Laura; Dawson, Ted M. // BMJ: British Medical Journal (International Edition);07/01/2000, Vol. 321 Issue 7252, p1 

    Editorial. Discusses a study which compares the incidence of dyskinesia with levodopa or ropinirole, a dopamine D2 receptor agonist, for the treatment of early Parkinson's disease. Methods of the study; Results, which indicate that initial treatment with ropinirole adequately controls symptoms...

  • Antiparkinsonian drugs and 'sleep attacks.' Moiler, Henry // CMAJ: Canadian Medical Association Journal;4/03/2001, Vol. 164 Issue 7, p1038 

    Reports on a side effect of the drugs ropinirole and pramipexole which cause some patients to suddenly fall asleep. Use of the drugs to treat Parkinson's disease; Theory that the drugs played a causative role in disregulating doparminergic input to the brain's reticular activating system, which...

  • First Successful Surgical Trial for Gene Therapy in Parkinson's Disease. Henchcliffe, Claire // Neurology Alert;May2011, Vol. 29 Issue 9, p65 

    THIS MULTICENTER, DOUBLE-BLIND, RANDOMIZED, SHAM-SURGERY CONtrolled trial examined the effects of introducing the glutamic acid decarboxylase (GAD) gene into the subthalamic nucleus (STN), bilaterally, of 45 individuals with advanced Parkinson's disease (PD), by means of the adeno-associated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics